COSMED - The Metabolic Company

A global, rapid diagnostics company specialising in world-class lateral flow technology.

Mologic has capabilities and proven expertise to take products through all phases of product development, from concept to commercialization and can provide high value contract services to assist through the innovation and development phases, including manufacturing scale-up.

Difficult technical problem solving, custom reagent development, recombinant protein expression, antibody production and custom production capability that incorporates low-mid volume manufacturing, are part of the offering that makes Mologic a unique end-to-end diagnostics service partner.

Our diverse skills enable our scientists to be truly innovative, seeing solutions that other organizations may never even consider.

Mologic has a broad pipeline that spreads across multiple markets and disease states. The pipeline includes diagnostic products for Respiratory Disease (predicting and diagnosing exacerbations for COPD and Cystic Fibrosis), Sepsis (confirmation), Women’s Health (Bacterial Vaginosis, Thrush, Urinary Tract Infection), Infection/Infectious Disease (Dialysis, Dengue, Malaria).

CE marked products include PERiPLEX® Peritoneal Dialysis Infection Diagnostic.

Mologic is seeking strategic partners for licensing and/or regional and global commercialisation of its products.

For more information, please email partners@mologic.co.uk

Pharma Stulln GmbH is specializing in sterile manufacturing. Eye drops, nasal sprays, respiratory solutions and lens-care products. High-performance bottelpack(R)-filling machines and a modern zone concept fulfills international standards for the production of sterile fluid pharmaceuticals.

Chiesi is an international company originated in Parma, with 85 years of experience and a strong focus on research, development, production and commercialization of innovative therapeutic solutions in the Respiratory, Neonatology, Rare Diseases and Special Care Therapeutic Areas. We are value-oriented, passionate, supportive and a global family with nearly 6.000 employees and 29 affiliates who have a real impact on people's lives in 90 countries around the world. With a turnover of nearly €2 billion sales, we are among the top 50 pharmaceutical companies in the world.
Chiesi is the largest global pharmaceutical Group to be awarded B Corp Certification, a recognition of high social and environmental standards. We want to use business as a force for good and create a positive impact on people, environment and community.

See our community guidelines: https://www.chiesi.com/en/linkedin-community-guidelines/

Crown CRO is a privately owned Finnish CRO founded in 2005. Our headquarters are in Espoo, which is located in Finland’s capital city region. Crown CRO offices are located in Finland, Sweden, Denmark, Norway, Estonia, Latvia and Lithuania. We have ongoing trials managed by our employees in Netherlands, Belgium, UK, Iceland, Ukraine and Belarus. Rest of the Europe and USA we cover through our qualified CRO network.

Our services cover Phase I – IV clinical development from protocol design to final reporting or any parts of the trial in various business models. Data services, Regulatory consulting, Pharmacovigilance, QA, Study Rescue Services and Medical Translation services complete the service package.

Our key therapeutic areas include, but not limited to, CNS, Oncology, Endocrinology, Cardiovascular, Respiratory and Musculoskeletal. We also have strong recent experience in Medical Devices from various indications.

Our passion for research across all our in-house Full-Service functions provide effective and innovative solutions with seamless cooperation for Phase I-III trials in Europe offering special focus on Nordic-Baltic area, together with our own Global Data Services ensuring consistency regardless of where your trials are located, offer you unrivalled customer attention, flexibility and high local level expertise which are key assets you can count on.

See www.crowncro.com for more information.

Founded in 1997, Ergomed plc is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with a strong heritage in the development of drugs in rare diseases and oncology.

• 1 300+ highly qualified professionals
• Global full-service CRO
• 24+ years of experience
• Therapeutic specialization in oncology
• Strong expertise in rare disease trials
• Robust clinical safety system
• Choice of leading drug safety databases

Our key services include:
• Clinical Research Services
• Pharmacovigilance
• Medical Information
• Regulatory
• Medical Writing
• Site Management
• Study Physician Support
• Biostatistics
• Patient Study Support